ARCHIVES

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

Reynolds Unveils New Cigarette ; Cullen, Others Skeptical

September 18, 1987

NCI Sets Initial R01 Payline At 18th Percentile Under CR.

November 24, 2000

ACS Recommends MRI For Some Women At High Risk

March 30, 2007

NIH Director Healy Resigned, To Return To Cleveland In June’ Kessler To Remain

March 5, 1993

NIH Grants: R29 Awards No Longer Accepted After June; NIH To Increase R01s.

December 5, 1997

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

December 2, 1983